Lowers the risk of myocardial infarction, myocardial revascularization procedures, and…. ANDA 207068, held by Accord Healthcare. Pravastatin Sodium.
As of Nov 21, 2026, ANDA 207068 (Pravastatin Sodium), held by Accord Healthcare, was first approved by FDA on Nov 17, 2016, with 4 approved supplements and 0 published complete response letters.
Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD). To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 2016 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Mar 17, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 17, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 13, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 5, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 17, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters